1997
Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)
Quirós P, Jones G, Kacinski B, Braverman I, Heald P, Edelson R, Wilson L. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). International Journal Of Radiation Oncology • Biology • Physics 1997, 38: 1027-1035. PMID: 9276369, DOI: 10.1016/s0360-3016(97)00127-2.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDisease-free survivalT2 patientsCrude relapse rateAdjuvant therapyOverall survivalElectron beam therapyRelapse rateEntire cohortMedian disease-free survivalCutaneous T-cell lymphomaBeam therapySalvage of recurrencesAdjuvant systemic therapyEarly-stage patientsManagement of patientsT-cell lymphomaTopical nitrogen mustardDays/weekCombination of therapiesGy/dayTreatments/weekPUVA patientsMedian followSalvage therapy
1995
Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy
Wilson L, Licata A, Braverman I, Edelson R, Heald P, Feldman A, Kacinski B. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. International Journal Of Radiation Oncology • Biology • Physics 1995, 32: 987-995. PMID: 7607973, DOI: 10.1016/0360-3016(95)00073-8.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDoxorubicin/cyclophosphamideCutaneous T-cell lymphoma patientsAdjuvant doxorubicin/cyclophosphamideT-cell lymphoma patientsExtracorporeal photochemotherapyComplete responseOverall survivalAdjuvant therapyElectron beam therapyAdjuvant regimenFree survivalCTCL patientsLymphoma patientsBeam therapyAddition of chemotherapyAdvanced stage CTCLClinical complete responseSystemic adjuvant therapyGood partial responseSignificant survival benefitBetter overall survivalRelapse-free survivalSoles of feetNontoxic regimenMalignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG, Wilson LD, Braverman IM, Feldman AM, Kacinski BM. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. JAMA Dermatology 1995, 131: 432-5. PMID: 7726585, DOI: 10.1001/archderm.131.4.432.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaT-cell lymphomaSquamous cell carcinomaBasal cell carcinomaElectron beam therapyAdditional radiation therapyCell carcinomaCutaneous malignanciesOral psoralenAdditional therapyMalignant melanomaRadiation therapyBeam therapyTotal skin electron beam radiationFurther radiation therapyGroup of patientsNonmelanoma skin cancerAnecdotal case reportsPrevious large studiesTopical mechlorethamineHydrochloride therapyCase reportPatientsCarcinoma